目的：评估Ahmed青光眼阀（Ahmed glaucoma valve，AGV）植入治疗难治性青光眼的长期疗效及并发症。 方法：回顾性分析13例13眼接受Ahmed青光眼阀植入，最短随访18mo的难治性青光眼患者。所有患者均在术前及术后1，3，6mo，1a及1a以后行全面的眼科检查，眼压测量,记录并发症及抗青光眼的药物需求。 结果：患者平均年龄27.3±16.0岁。所有患眼（100%）接受至少一次前置小切口手术。平均随访61.3±30.8mo。在少量药物的作用下，12mo时眼压由35.0±7.0mmHg降至18.2±7.9mmHg，96mo时降至17.0±4.1mmHg，76.9%患者需其他辅助治疗以达到预期的成功疗效。最常见的并发症包括包裹性囊肿8眼(61.5%)，置管脱出4眼(30.8%)。 结论：包裹性囊肿是最常见的并发症，阻碍了Ahmed青光眼阀植入治疗难治性青光眼。虽然囊肿被抗纤维化药物切除，但没有抗青光眼药物的治疗，眼压仍旧不能很好控制。

AIM: To evaluate the long-term results and complications of Ahmed glaucoma valve (AGV) implantation in refractory glaucoma. METHODS: A retrospective review of 13 patients (13 eyes) with refractory glaucoma who underwent AGV implantation and had a minimum follow-up of 18 months was performed. All patients underwent a complete ophthalmologic examination and intraocular pressure(IOP) measurement before surgery and at 1 month, 3 months, 6 months, 1 year after surgery and yearly afterwards. Complications and the number of antiglaucoma medications needed were recorded. RESULTS: Mean age was 27.3±16.0 years. All eyes (100%) had at least one prior incisional surgery. Mean follow-up was 61.3±30.8 months. IOP was reduced from a mean of 35.0±7.0mmHg to 18.2±7.9mmHg at 12 months and to 17.0±4.1mmHg at 96 months (P<0.05) with a lower number of medications from baseline, 76.9% patients required additional procedures to achieve the success criteria set by previously published series. The most common complications were encapculated cyst formation in eight eyes (61.5%) and tube exposure in four eyes (30.8%). CONCLUSION: Encapsulated cyst formation was the most common complication which hindered succesful IOP control after AGV implant insertion for refractory glaucoma. Despite cyst excision with anti-fibrotic agents, successful IOP reduction was not achieved in 76.9% of the patients without antiglaucoma medication.